All In Biotech

Drug Trial Radar · NCT05544565

3-day IV Antibiotic Treatment Versus 3-day IV Followed by 7-day Oral Antibiotic Treatment for AP in Children

3-day Intravenous Antibiotic Treatment Versus 3-day Intravenous Followed by 7-day Oral Antibiotic Treatment for Acute Pyelonephritis in Children 1 Month to 3 Years Old: a Non-inferiority Open Randomized Multicentric Clinical Trial

Last checked: Nov 19, 2026Latest source record: Jan 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 480 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

480

Planned (sponsor's estimate)

Start

Mar 22, 2023

Primary completion

Jan 2028

Study completion Jan 2028

Sponsor

Lead sponsor
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 16, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 1 month, up to 3 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Antibiotic therapies currently recommended for the treatment of acute pyelonephritis (AP) in children, whether fully by the oral route or initially intravenous (IV, 3 days) followed by the oral route, have a duration of 7 to 14 days (10 days in France). In children with no prior urological malformation, the global clinical and microbiological cure rate after antibiotic treatment completion is around 95%. Recurrence occurs in less than 5% of cases in the 3 months following AP. Renal scarring, when documented, concerns 15% of children 6 months after treatment. Renal scarring can be associated with chronic renal disease. The investigators hypothesize that 3 days of IV treatment is equivalent to extending to 10 days with an oral to treat AP in children. The investigators also hypothesize that while achieving equivalent clinical and prevention of re-infections in the following 3 months, 3 days of IV treatment reduces the risk of acquisition of resistant strains of Enterobacteriaceae and increases the gut microbotia diversity compared to extending to 10 days with an oral therapy.

Conditions

  • Pyelonephritis Acute

Interventions

  • IV Antibacterial AgentsDrug

    Ceftriaxone (50 mg/kg once a day by intravenous/intramuscular route) AND/OR Amikacin (20 mg/kg once a day by intravenous/intramuscular route) during 3 days. .

  • Orally antibacterial agentsDrug

    Cotrimoxazole (sulfamethoxazole/trimethoprime) 30mg/kg/day (2 divided doses) OR Cefixime 8mg/kg/day (2 divided doses) during 7 days

  • Fecal/Rectal SwabProcedure

    Collected by the nurse or the physician (D0,D3,D10 or 17 and D31 or D38), either by a rectal swab, either by fecal swab (dip of the swab in fresh stools \< 4 hours, which will occur frequently in our population of children aged 1 month to 3 years, and will in particular be possible for hospitalized children) using a FecalSwabTM, that contains a transport medium.

  • PCT assayProcedure

    Dosage of procalcitonin (if not performed in standard care) at D0

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Recurrence of febrile urinary tract infectionTime frame: 28 days (± 3 days) after the completion of antibiotic treatment.

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • GHEF Site Marne la vallée

    Jossigny, France · Not yet recruiting

  • CHU Toulouse

    Toulouse, France · Not yet recruiting

  • CH Sud Francilien

    Corbeil-Essonnes, Essonne, France · Not yet recruiting

  • Paris-Saclay hospital

    Orsay, Essonne, France · Recruiting

  • Antoine Beclère Hospital

    Clamart, Haut de Seine, France · Not yet recruiting

  • Ambroise Paré hospital

    Boulogne, Hauts de Seine, France · Recruiting

  • Children-Teenager hospital

    Nantes, Loire Atlantique, France · Not yet recruiting

  • Jeanne Flandre Hospital

    Lille, Nord, France · Not yet recruiting

  • Robert Debré Hospital

    Paris, Paris, France · Not yet recruiting

  • Robert Debré Hospital

    Paris, Paris, France · Not yet recruiting

  • Meaux Hospital

    Meaux, Seine et Marne, France · Not yet recruiting

  • Jean Verdier Hospital

    Bondy, Seine St Denis, France · Not yet recruiting

  • Intercomunal Créteil Hospital

    Créteil, Val de Marne, France · Not yet recruiting

  • Kremlin Bicêtre Hospital

    Le Kremlin-Bicêtre, Val de Marne, France · Not yet recruiting

  • Andre mignot hospital

    Le Chesnay, Yvelines, France · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.